P
Protillion
Specializes in the design and development of protein-based drugs
About Protillion
Protillion Biosciences is a biotechnology startup that operates in the field of therapeutic protein discovery and optimization. The company uses next-generation technologies to generate quantitative protein data at an unprecedented scale, aiming to bring the best therapeutic candidates to light. Their primary clients are likely to be pharmaceutical companies and research institutions that are involved in drug discovery and development.
Read full description
Protillion's business model revolves around the use of revolutionary technology to quantitatively characterize protein candidates at a massive scale. This allows them to discover therapeutic molecules with precisely tuned affinity and uncompromised manufacturability. The company's high throughput protein analysis chip and comprehensive quantitative data for the entire library are key components of this process.
The company also emphasizes the importance of pairing revolutionary computational approaches to drug discovery with exceptional wet experimentation for training and validation. This suggests a hybrid approach that combines advanced technology with traditional laboratory methods.
Protillion recently raised $18 million in financing, led by ARCH Venture Partners and Illumina Ventures. This indicates strong financial backing and potential for growth.
In terms of revenue generation, while specific details are not provided, it's likely that Protillion makes money by licensing its technology and data to pharmaceutical companies and research institutions, and potentially through partnerships and collaborations in drug discovery and development.
At a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- Carlsbad, United States
- Employees
- 22
- Open positions
- 1
- Dealroom signal
- 74.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Protillion.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Dec 2022 | $18M | $72M | Illumina Ventures · ARCH Venture Partners | ↗ |
| SPINOUT✓Other financing | Jan 2019 | $0 | — | Stanford University | — |
Growth signals
Latest recorded traffic for Protillion is 2K monthly website visits, down 20% over the last three months. Protillion's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Illumina Ventures
ARCH Venture Partners
Other known investors2 additional known investors
Stanford University
Creative Destruction Lab
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Protillion on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Protillion’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.